We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds

By LabMedica International staff writers
Posted on 09 Feb 2024

Fentanyl, a synthetic opioid recognized by the Centers for Disease Control and Prevention as being 50 times more potent than heroin and 100 times more potent than morphine, is often illicitly combined with other drugs. More...

Just 2 milligrams of fentanyl, roughly equivalent to 10 to 15 grains of table salt, can be fatal. Daily, over 150 people succumb to overdoses involving synthetic opioids such as fentanyl. Research has shown that fentanyl can be detected in urine up to 72 hours after use. Now, researchers have developed a first-of-its-kind, handheld device that is capable of accurately detecting fentanyl in urine within seconds.

The device developed by researchers at University of Texas at Dallas (Richardson, TX, USA) contains an electrochemical sensor that operates by generating electrical signals from chemical reactions. Detecting fentanyl was challenging due to its nonvolatile nature, meaning it doesn't naturally produce an electrochemical signature. To overcome this, the researchers designed a molecular cage-like structure resembling a mousetrap to capture fentanyl. This "trap" incorporates several components, including gold nanoparticles, and utilizes naloxone, a medication that reverses opioid overdoses, to attract and bind to fentanyl. When a urine sample is applied to a test strip, the presence of fentanyl triggers a reaction with the naloxone, resulting in a detectable signal.

This technology can also test other substances for fentanyl by simply diluting a sample in water and applying it to the sensor. The team's proof-of-concept device can detect trace amounts of fentanyl with 98% accuracy, bypassing the need for expensive and time-consuming lab analyses. The current prototype, designed for urine testing, is a precursor to developing a saliva-based test. Efforts are underway to expand the technology for detecting fentanyl in hair, with the ultimate goal being a saliva test. A saliva-based test would be particularly beneficial for first responders in making timely treatment decisions for overdose cases.

“There is an urgent demand for an easy-to-use, portable, miniaturized device that can detect fentanyl with high specificity and share results immediately to an internet-connected device,” said Dr. Shalini Prasad, professor and department head of bioengineering in the Erik Jonsson School of Engineering and Computer Science. “Our study demonstrates the feasibility of a highly accurate sensor to detect fentanyl within seconds.”

Related Links:
University of Texas at Dallas


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.